These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35722762)

  • 21. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
    Martin NK; Vickerman P; Brew IF; Williamson J; Miners A; Irving WL; Saksena S; Hutchinson SJ; Mandal S; O'Moore E; Hickman M
    Hepatology; 2016 Jun; 63(6):1796-808. PubMed ID: 26864802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Telemedicine HCV treatment in department of corrections results in high SVR in era of direct-acting antivirals.
    Syed TA; Cherian R; Lewis S; Sterling RK
    J Viral Hepat; 2021 Jan; 28(1):209-212. PubMed ID: 32854135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elimination of hepatitis C virus in a prison: An 18-year experience.
    Nogales-Garcia M; Parraza Diez N; Vargas Axpe A; Velasco Garcia R; Larrabeiti-Etxebarria A; Roy Lopez-Cano I; Atrio Alvarez I; Lopez de Arcaute Trincado A; Fernandez Lopez de Vicuña EM; Saez de Adana Arroniz E; Martínez Martínez C; Portu Zapirain J
    Enferm Infecc Microbiol Clin (Engl Ed); 2024 May; 42(5):236-241. PubMed ID: 37117143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era.
    Brzdęk M; Zarębska-Michaluk D; Rzymski P; Lorenc B; Kazek A; Tudrujek-Zdunek M; Janocha-Litwin J; Mazur W; Dybowska D; Berak H; Parfieniuk-Kowerda A; Klapaczyński J; Sitko M; Sobala-Szczygieł B; Piekarska A; Flisiak R
    World J Gastroenterol; 2023 Apr; 29(13):2015-2033. PubMed ID: 37155527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine.
    Morey S; Hamoodi A; Jones D; Young T; Thompson C; Dhuny J; Buchanan E; Miller C; Hewett M; Valappil M; Hunter E; McPherson S
    J Viral Hepat; 2019 Jan; 26(1):101-108. PubMed ID: 30315691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study.
    Choi GH; Jang ES; Kim YS; Lee YJ; Kim IH; Cho SB; Lee HC; Jang JW; Ki M; Choi HY; Baik D; Jeong SH
    World J Gastroenterol; 2022 Aug; 28(30):4182-4200. PubMed ID: 36157119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
    Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
    World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
    Martin MT; Deming P
    Pharmacotherapy; 2017 Jun; 37(6):735-747. PubMed ID: 28374965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response?
    Sterling RK; Hofmann CM; Luketic VA; Sanyal AJ; Contos MJ; Mills AS; Shiffman ML
    Am J Gastroenterol; 2004 May; 99(5):866-72. PubMed ID: 15128352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting.
    Overton K; Clegg J; Pekin F; Wood J; McGrath C; Lloyd A; Post JJ
    Int J Drug Policy; 2019 Oct; 72():123-128. PubMed ID: 30967329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-life experience of hepatitis C treatment in a Spanish prison.
    Tejera-Pérez RJ; Iglesias-Gómez A; Oliva-Oliva A; Rodríguez-Alonso B; Alonso-Sardón M; Sánchez Ledesma M; Carbonell-Muñoz C; Pendones Ulerio J; Muñoz-Bellido JL; Belhassen-García M
    Rev Esp Quimioter; 2022 Jun; 35(3):273-278. PubMed ID: 35441836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry.
    Krüger K; Krauth C; Rossol S; Mauss S; Boeker KHW; Müller T; Klinker H; Pathil A; Heyne R; Stahmeyer JT;
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):230-240. PubMed ID: 30325794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment and re-treatment results of HCV patients in the DAA era.
    Piecha F; Gänßler JM; Ozga AK; Wehmeyer MH; Dietz J; Kluwe J; Laschtowitz A; von Felden J; Sterneck M; Jordan S; Pischke S; Lohse AW; Schulze Zur Wiesch J
    PLoS One; 2020; 15(5):e0232773. PubMed ID: 32369527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study.
    Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B;
    Clin Infect Dis; 2022 Nov; 75(10):1809-1819. PubMed ID: 35362522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
    Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
    Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High rate of hepatitis C reinfection following antiviral treatment in the North East England Prisons.
    Bhandari R; Morey S; Hamoodi A; Thompson C; Jones D; Hewett M; Hunter E; Taha Y; McPherson S
    J Viral Hepat; 2020 Apr; 27(4):449-452. PubMed ID: 31749225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
    Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
    Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
    Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
    J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consensus recommendations on the management of hepatitis C in Australia's prisons.
    Winter RJ; Sheehan Y; Papaluca T; Macdonald GA; Rowland J; Colman A; Stoove M; Lloyd AR; Thompson AJ
    Med J Aust; 2023 Mar; 218(5):231-237. PubMed ID: 36871200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.